These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9511079)

  • 21. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
    Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
    J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections.
    Goff DA; Sierawski SJ
    Pharmacotherapy; 2002 Jun; 22(6):748-58. PubMed ID: 12066965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species.
    Cormican MG; Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1996 Jan; 24(1):59-60. PubMed ID: 8988766
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
    Ristow TA; Noskin GA; Warren JR; Peterson LR
    Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.
    Chow JW; Donahedian SM; Zervos MJ
    Clin Infect Dis; 1997 Jan; 24(1):90-1. PubMed ID: 8994759
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of vancomycin-resistant Enterococcus faecium infections.
    Lai KK
    Arch Intern Med; 1996 Dec 9-23; 156(22):2579-84. PubMed ID: 8951301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with quinupristin/dalfopristin after bacteremia persisted with alatrofloxacin therapy.
    Zaman MM; Recco R; Tejwani U; Scuto TJ; Ahmed S; Hypolite A; Jayaraman G
    Clin Infect Dis; 1999 Oct; 29(4):954-5. PubMed ID: 10589932
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns.
    Furlong WB; Rakowski TA
    Clin Infect Dis; 1997 Jul; 25(1):163-4. PubMed ID: 9243059
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
    Bozdogan B; Leclercq R
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
    Erlandson KM; Sun J; Iwen PC; Rupp ME
    Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis.
    Fantin B; Leclercq R; Garry L; Carbon C
    Antimicrob Agents Chemother; 1997 May; 41(5):931-5. PubMed ID: 9145847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance mechanisms and clinical characteristics of linezolid-resistant Enterococcus faecium isolates: A single-centre study in South Korea.
    Cho SY; Kim HM; Chung DR; Kim SH; Huh HJ; Kang CI; Peck KR; Lee NY; Song JH
    J Glob Antimicrob Resist; 2018 Mar; 12():44-47. PubMed ID: 28941790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.
    Bethea JA; Walko CM; Targos PA
    Ann Pharmacother; 2004 Jun; 38(6):989-91. PubMed ID: 15100393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
    Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
    Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.